Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | ODC1 | P11926 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2475408 | 0.83 | CACNA2D1 (0.41) | GABRR1ODC1DPP8DPP7DPP4 | |
| Trifluoroacetic Acid SCHEMBL8529046 | 0.83 | GABRR1 (0.45) | GABRR1ODC1KDM4ELMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL21199352 | 0.82 | GABRR1 (0.41) | GABRR1ODC1HRH4HRH3GABBR2 | |
| Trifluoroacetic Acid SCHEMBL29019099 | 0.81 | GABRR1 (0.41) | GABRR1ODC1KDM4ELMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL30164390 | 0.78 | BLM (0.43) | BLMPMP22DPP8DPP7DPP4 | |
| Trifluoroacetic Acid SCHEMBL27664147 | 0.78 | BLM (0.43) | BLMPMP22DPP8DPP7DPP4 | |
| Trifluoroacetic Acid SCHEMBL30140901 | 0.78 | BLM (0.43) | BLMPMP22DPP8DPP7DPP4 | |
| Trifluoroacetic Acid SCHEMBL3149196 | 0.78 | ODC1 (0.48) | GABRR1ODC1KDM4ELMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL10619767 | 0.78 | ODC1 (0.48) | GABRR1ODC1KDM4ELMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL6490887 | 0.78 | HRH4 (0.50) | GABRR1ODC1KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867654-A | RNA constructs and uses thereof | 生物技术欧洲股份公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115843330-A | Coronavirus vaccine | 辉瑞公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-115811986-A | Coronavirus vaccine | 生物技术欧洲股份公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-115569151-A | Adipose tissue-derived stromal stem cells for the treatment of refractory, complex perianal fistulas in crohn's disease | 武田药品工业株式会社 | 2023-01-06 | — | — | CN | disclosed |
| CN-115427432-A | Vaccine agent for treating or preventing coronavirus disease mutant strain | 斯微(上海)生物科技股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-108883135-B | Adipose tissue-derived stromal stem cells for the treatment of refractory, complex perianal fistulas in crohn's disease | 武田药品工业株式会社 | 2022-11-04 | — | — | CN | disclosed |
| US-11364259-B2 | MRNA functionalization method | THE UNIVERSITY OF TOKYO (JP) | 2022-06-21 | — | — | US | disclosed |
| WO-2022004765-A1 | COMPOSITION FOR GENOME EDITING | 公益財団法人川崎市産業振興財団 | 2022-01-06 | — | — | WO | disclosed |
| CN-113521269-A | Coronavirus vaccine | 生物技术RNA制药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113521268-A | Coronavirus vaccine | 生物技术RNA制药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021131116-A1 | CARRIER FOR CELL DELIVERY | 株式会社アイ・ティー・オー | 2021-07-01 | — | — | WO | disclosed |
| US-20200347385-A1 | METHOD FOR mRNA STABILIZATION | THE UNIVERSITY OF TOKYO (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3708664-A1 | METHOD FOR mRNA STABILIZATION | The University Of Tokyo (JP) | 2020-09-16 | — | — | EP | disclosed |
| EP-3564375-A1 | MRNA FUNCTIONALIZATION METHOD | The University Of Tokyo (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20190328769-A1 | MRNA FUNCTIONALIZATION METHOD | THE UNIVERSITY OF TOKYO (JP) | 2019-10-31 | — | — | US | disclosed |
| EP-1514869-A1 | INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-0190891-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364259-B2 | MRNA functionalization method | RNGTT, RNMT, NSUN3 | GABRR1 1678/4885ODC1 1957/4885KDM4E 4252/4885 |
| US-20190328769-A1 | MRNA FUNCTIONALIZATION METHOD | RNGTT, RNMT, NSUN3 | GABRR1 1678/4885ODC1 1957/4885KDM4E 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.